New Hope in the Battle Against Ovarian Cancer
There is commercial interest in developing personalised medical care. Ovarian cancer is a possibly lucrative opportunity. AI predictive models are using large data sets of patient drug-treatment protocols, genetic information and historical outcomes to develop targeted therapeutics.
In collaboration with the UK 100,000 Genomes Project, which is an NHS project collecting genetic material from cancer patients, a US biotechnology company; Helomics currently has data from 38,000 cases of ovarian cancer.
Helomics is looking at genetic variations and expression together with its data set of drug-response profiles to build an AI-driven predictive model of ovarian cancer. This will guide clinicians, as to which drug or drug combinations to use for ovarian cancer treatments.
No comments:
Post a Comment